{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "cancer therapy",
      "p53",
      "synthetic lethality"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25960041",
  "DateCompleted": {
    "Year": "2016",
    "Month": "05",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "07",
    "Day": "25"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2015",
        "Month": "05",
        "Day": "07"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.tcb.2015.04.001",
      "S0962-8924(15)00066-5"
    ],
    "Journal": {
      "ISSN": "1879-3088",
      "JournalIssue": {
        "Volume": "25",
        "Issue": "8",
        "PubDate": {
          "Year": "2015",
          "Month": "Aug"
        }
      },
      "Title": "Trends in cell biology",
      "ISOAbbreviation": "Trends Cell Biol"
    },
    "ArticleTitle": "Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation.",
    "Pagination": {
      "StartPage": "486",
      "EndPage": "495",
      "MedlinePgn": "486-95"
    },
    "Abstract": {
      "AbstractText": [
        "The tumor suppressor protein p53 plays a critical role in limiting malignant development and progression. Almost all cancers show loss of p53 function, through either mutation in the p53 gene itself or defects in the mechanisms that activate p53. While reactivation of p53 can effectively limit tumor growth, this is a difficult therapeutic goal to achieve in the many cancers that do not retain wild type p53. An alternative approach focuses on identifying vulnerabilities imposed on cancers by virtue of the loss of or alterations in p53, to identify additional pathways that can be targeted to specifically kill or inhibit the growth of p53 mutated cells. These indirect ways of exploiting mutations in p53 - which occur in more than half of all human cancers - provide numerous exciting therapeutic possibilities."
      ],
      "CopyrightInformation": "Copyright \u00a9 2015 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cancer Research UK Beatson Institute, Glasgow, UK."
          }
        ],
        "LastName": "Gurpinar",
        "ForeName": "Evrim",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cancer Research UK Beatson Institute, Glasgow, UK. Electronic address: k.vousden@beatson.gla.ac.uk."
          }
        ],
        "LastName": "Vousden",
        "ForeName": "Karen H",
        "Initials": "KH"
      }
    ],
    "GrantList": [
      {
        "GrantID": "C596/A10419",
        "Agency": "Cancer Research UK",
        "Country": "United Kingdom"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Trends Cell Biol",
    "NlmUniqueID": "9200566",
    "ISSNLinking": "0962-8924"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Tumor Suppressor Protein p53"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Cell Cycle Checkpoints"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Tumor Suppressor Protein p53"
    }
  ]
}